Roivant (ROIV) Q1 2026 earnings review
Massive Liquidity Funds Accelerating Pipeline and Stock Buybacks
Roivant is entering a critical transition phase from a clinical-stage biotech to a commercial entity, backed by an fortress balance sheet. The company ended Q1 with $3.9B in cash and investments, not including a massive $950M litigation settlement payment received in July. This capital abundance allowed Roivant to do something incredibly rare for a pre-profit biotech: repurchase $208.7M of its own stock. Operating expenses are accelerating, with R&D up 32% YoY to $202.0M as the anti-FcRn and mosliciguat programs advance. The focus now shifts entirely to execution, with the brepocitinib commercial launch in DM expected in September and a catalyst-rich second half of 2026.
🐂 Bull Case
With pro-forma cash of approximately $4.85 billion (including the July Moderna payment), management explicitly states they have a runway into profitability. This eliminates dilution risk and allows aggressive concurrent advancement of multiple late-stage programs.
Brepocitinib is on track for commercial launch in dermatomyositis (DM) by the end of September 2026, transitioning Roivant into a commercial-stage company and providing a foundation for a multi-indication franchise.
🐻 Bear Case
Total operating expenses surged to $367.8M in the quarter. While fully funded, the cost of running simultaneous global Phase 3 trials across Priovant, Immunovant, and Pulmovant is rapidly increasing the baseline burn rate.
As previously warned by management, the phenomenal Period 1 RA data for IMVT-1402 sets a difficult statistical bar for the upcoming Period 2 withdrawal phase. Additionally, the CLE data expected in H2 faces a highly competitive landscape.
⚖️ Verdict: 🟢
Bullish. It is extraordinarily rare to find a biotech with a late-stage, multi-franchise pipeline that is entirely derisked from a capital perspective. The decision to buy back $208.7M in stock signals immense management confidence.
Key Themes
Catalyst-Rich H2 2026 Pipeline Readouts
Roivant is entering a dense data-readout period in the second half of 2026. Key expected milestones include topline data for the Phase 3 NIU study (brepocitinib), the proof-of-concept trial in CLE (IMVT-1402), and the Phase 2 PH-ILD study (mosliciguat). Success in any of these indications unlocks massive total addressable markets.
Expanding Global Patent Litigation
Following the $2.25B settlement with Moderna, Genevant and Arbutus are aggressively pursuing Pfizer and BioNTech. In July 2026, they filed new lawsuits spanning 21 jurisdictions, including Canada and 20 European countries via the Unified Patent Court (UPC). This geographic expansion significantly raises the pressure on Pfizer/BioNTech and creates a massive new potential revenue stream.
Clinical vs. Hemodynamic Endpoints for Mosliciguat
The Phase 2 study for mosliciguat in PH-ILD expects topline data in H2 2026. The primary endpoint is Pulmonary Vascular Resistance (PVR) change. As previously noted by management, the study is not powered for the 6-minute walk distance—the likely Phase 3 clinical endpoint. There is a risk that the drug shows hemodynamic success but leaves clinical efficacy ambiguous.
Anti-FcRn R&D Accelerating
The Immunovant franchise continues to consume the lion's share of new investment. Program-specific R&D costs increased by $49.4M YoY, with $44.8M of that increase directly related to the anti-FcRn franchise. This reflects the broad, aggressive development of IMVT-1402 across potentially registrational trials in GD, MG, CIDP, D2T RA, and SjD.
One-Time Settlement Bonuses Inflating G&A
G&A expenses accelerated from $134.0M to $165.5M YoY. This was largely driven by $18.8M in employee bonuses tied directly to the global settlement reached with Moderna in March 2026, plus $6.3M in employer payroll taxes on equity awards. Investors must normalize these figures to understand the true ongoing G&A run-rate.
Other KPIs
The balance sheet reported $3.9 billion at quarter-end, but this explicitly excludes the $950 million non-contingent cash payment received from Moderna in July 2026. This combined liquidity ensures the company will not need to tap equity markets for the foreseeable future, fully funding operations into profitability.
In Q1 2026, Roivant repurchased 7.3 million common shares. For a company that still recorded a $290M net loss, utilizing capital for buybacks is highly unusual and demonstrates management's belief that the market is severely undervaluing the sum-of-the-parts pipeline.
Accelerating. Up from $152.9M a year ago. Non-GAAP R&D was $192.9M. The trajectory reflects the maturation of the pipeline as Phase 2 and Phase 3 trials scale up globally, specifically for IMVT-1402 and mosliciguat.
Guidance
Stable. The timeline for commercial preparations remains on track for Q3 2026, marking Roivant's first major transition to commercial-stage revenue generation for this asset.
Stable. Topline data for the inhaled sGC activator remains on track for the second half of the year, serving as a massive potential catalyst for the Pulmovant subsidiary.
Stable. Topline data is expected before year-end, testing the drug in cutaneous lupus erythematosus. Management has previously noted the high competitive bar for success in this indication.
Key Questions
Brepocitinib Launch Metrics
As we approach the DM launch in September, what leading indicators (formulary access, salesforce deployment) can you share regarding commercial readiness, and how quickly do you expect to penetrate the target patient population?
Pfizer/BioNTech Litigation Strategy
With the expansion into 21 new jurisdictions including the UPC, what is the anticipated timeline for the first substantive rulings in these international courts compared to the ongoing U.S. discovery phase?
Capital Allocation Following Buybacks
You repurchased nearly $209M in stock this quarter. With pro-forma cash near $4.85B, how do you weigh further buybacks against potential in-licensing or M&A opportunities in the current biotech valuation environment?